Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study
about
Chapter 7: PharmacogenomicsHow drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusionSLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalinkStatins: Cholesterol guidelines and Indian perspectiveGenetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic reviewClinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementationPharmacogenomics of adverse drug reactionsPhenotype standardization for statin-induced myotoxicityNon-cardiovascular effects associated with statinsAssociation between SLCO1B1 -521T>C and -388A>G polymorphisms and risk of statin-induced adverse drug reactions: A meta-analysisPharmacogenomics of statins: understanding susceptibility to adverse effectsStatin intolerance - a question of definition.Statin pharmacogenomics: pursuing biomarkers for predicting clinical outcomes.Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary aSafety of statins: an updateExpression of mRNA transcripts encoding membrane transporters detected with whole transcriptome sequencing of human brain and liverPharmacogenetics of Statin-Induced Myopathy: A Focused Review of the Clinical Translation of Pharmacokinetic Genetic VariantsPharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins.Prevalence of genetic variants associated with cardiovascular disease risk and drug response in the Southern Indian population of Kerala.Statin pharmacogenomics: opportunities to improve patient outcomes and healthcare costs with genetic testingPharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.Genetically guided statin therapy on statin perceptions, adherence, and cholesterol lowering: a pilot implementation study in primary care patients.[Pharmacogenomic Biomarkers for the Prediction of Statin Efficacy and Safety].Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel.Pharmacogenomics: application to the management of cardiovascular diseaseCardiovascular pharmacogenomicsSLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study.Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutionsAssociation Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case-Control StudiesSLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization.Pharmacogenetics and cardiovascular disease--implications for personalized medicineGenetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis.SLCO1B1 Polymorphisms and Statin-Induced Myopathy.Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sexPharmacogenomics and adverse drug reactions: the case of statins.Genetic determinants of response to cardiovascular drugs.Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism.Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia.
P2860
Q21563496-238F3EE0-529D-4D06-BA34-FE9B07F4DE45Q24273350-649D9D5C-74E7-4CDF-BEB0-0CE030EA0F42Q24598793-69D21472-047F-47D9-B681-E0E059654A50Q26783226-527B7176-287B-40D5-BEF7-583A29C7B2FDQ26823434-DE36404B-E579-40A8-8419-BA92AE54B289Q27011524-9D4F1F2F-6B59-45DE-902A-2E21D84D6140Q27015820-1C8B0B00-A1D8-466B-A22F-3C22C35CDCC9Q27020935-E2AE4058-463E-4788-8E7C-2B1178044D7DQ27026332-60DAE99C-BEB7-4537-AFA0-ADD6B4E3EC80Q28070052-E4B915DC-484F-4161-90A9-53E82ACF0F3CQ28079822-D7643FEA-EDDD-4B3B-9FD2-10D3DFFC4545Q30245218-E65F520D-2F47-4671-BE6F-ADAA1C4CD14AQ33690357-BCD472CF-2206-4A41-A255-BD368A51AF1BQ33948919-B0183A2F-B9C0-45F1-BFD8-982B7681F0D2Q33949312-750CC81F-8263-4587-945C-4DDB7EF1BEFEQ34042444-3F1D63F7-28CF-448D-BEB2-D705125F540FQ34163351-A9F35D75-CC48-4743-83F6-74D1F3B2C437Q34453666-0B23F3BE-5A42-4289-A7B0-4E248BF23266Q34494596-93EF71E9-63A4-40DF-8D64-02C63A149A47Q34608646-0BEE8070-ED20-4DEA-8AB2-A23D7FC345F7Q34680467-4ABAC474-1E16-484F-908D-1F8A8AE7C5CEQ34683910-D682DE06-C2BD-448F-AA85-E046FCB31F34Q35158967-DFF4D7D3-9370-49CD-9190-08D2B7D0B2FBQ35232279-939D8739-4D2B-49C3-AFA1-4769AB4D602DQ35309161-263C6133-715E-4848-917D-DC71B750397AQ35447163-3078DB29-57AD-472B-8FC4-996A20EEB4D8Q35669829-7F13EBD2-902C-44F9-B314-E25056CB0619Q35675566-FD6A55E8-93F4-4F26-A341-D2F425C75ECBQ35915932-F8B4DB03-DE7C-4E24-8C8F-F4036B532AAEQ36256049-3D489112-E3A1-48A1-8F79-43EAD1A7351BQ36480609-8FF9A3B5-E04F-4C15-821F-D96E31B0D58AQ36974672-DFE3E438-141D-4DFE-AD32-C315DC6F47FFQ36998199-7848D059-7A95-47B0-91AA-80039F28F617Q37279044-AF9B2538-5029-46A5-A03A-ADA3596E3A62Q37410969-D95A6730-629E-421A-A160-53FB0BA670A2Q37422685-41C01859-06ED-4BB6-8C31-CBE065BF9C87Q37875115-1EE6D5FE-776E-4F9E-812E-8F71545350C6Q37989811-60A2093C-11EA-4A99-B29D-A90BD891DED5Q38084901-E38F1D95-3138-4F2E-8DBB-7AC87D93959AQ38097339-EAB98871-BD15-470E-B942-903C3228EE46
P2860
Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Common nonsynonymous substitut ...... e 2 diabetes: a go-DARTS study
@ast
Common nonsynonymous substitut ...... e 2 diabetes: a go-DARTS study
@en
type
label
Common nonsynonymous substitut ...... e 2 diabetes: a go-DARTS study
@ast
Common nonsynonymous substitut ...... e 2 diabetes: a go-DARTS study
@en
prefLabel
Common nonsynonymous substitut ...... e 2 diabetes: a go-DARTS study
@ast
Common nonsynonymous substitut ...... e 2 diabetes: a go-DARTS study
@en
P2093
P2860
P356
P1476
Common nonsynonymous substitut ...... e 2 diabetes: a go-DARTS study
@en
P2093
A D Morris
A S F Doney
A T Hattersley
C N A Palmer
E R Pearson
H M Colhoun
L A Donnelly
M I McCarthy
R Tavendale
P2860
P2888
P304
P356
10.1038/CLPT.2010.255
P407
P50
P577
2010-12-22T00:00:00Z
P5875
P6179
1043563082